Alnylam Q4 net product revenue misses expectations

Reuters02-12
Alnylam Q4 net product revenue misses expectations

Overview

  • RNAi therapeutics firm's Q4 net product revenue grew 121% yr/yr but missed expectations

  • Adjusted EPS for Q4 beat analyst expectations

  • Company launched 'Alnylam 2030' strategy and plans $250 mln manufacturing expansion

Outlook

  • Alnylam expects 2026 total net product revenues between $4.9 bln and $5.3 bln

  • Company projects 2026 TTR net product revenues of $4.4 bln to $4.7 bln

  • Alnylam plans $250 mln investment in manufacturing expansion

Result Drivers

  • AMVUTTRA SUCCESS - The approval and launch of AMVUTTRA for ATTR-CM in the U.S. significantly drove revenue growth, with AMVUTTRA generating $827 mln in Q4 2025

  • PIPELINE EXPANSION - Initiated multiple clinical trials and expanded pipeline with proprietary CTAs, enhancing future growth prospects

  • MANUFACTURING INVESTMENT - Announced $250 mln investment in a new RNAi manufacturing facility to expand capacity and reduce costs

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Product Revenue

Miss

$1.10 bln

$1.17 bln (20 Analysts)

Q4 Adjusted EPS

Beat

$1.28

$1.12 (15 Analysts)

Q4 Adjusted Net Income

$169.75 mln

Q4 Net Income

$111.54 mln

Q4 Adjusted Operating income

$203.35 mln

Q4 Operating Income

$131.72 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Alnylam Pharmaceuticals Inc is $489.00, about 51.7% above its February 11 closing price of $322.28

  • The stock recently traded at 49 times the next 12-month earnings vs. a P/E of 82 three months ago

Press Release: ID:nBw213R4Wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment